Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802411 · ClinicalTrials.gov registry record · Phase 3
Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 191
- Enrollment target
NCT01802411 is a Phase 3 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 191 participants.
The verdict
NCT01802411, a Phase 3 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
Interventions
- DRUG Placebo
- DRUG EXPAREL 266 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01802411
The ClinicalTrials.gov registry entry for NCT01802411 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01802411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01802411 about?
NCT01802411 is a clinical study titled "Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy". The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
What is the current status of trial NCT01802411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 191 participants. The study started on 2012-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01802411?
The interventions under investigation include: Placebo (DRUG), EXPAREL 266 mg (DRUG).
Who is sponsoring clinical trial NCT01802411?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.